In terms of future clinical perspectives, therefore, TRAIL appears to be an attractive therapeutic target, and TRAIL-based approaches interfering with TRAIL pathways have already demonstrated therapeutic potential, particularly in Alzheimer’s disease and EAE/MS (Fig. 2). The gene discussed is TNFSF10; the disease is early-onset autosomal dominant Alzheimer disease.